Results 41 to 50 of about 4,689 (214)

Acute Effects of Lysergic Acid Diethylamide on Circulating Steroid Levels in Healthy Subjects [PDF]

, 2016
Lysergic acid diethylamide (LSD) is a serotonin 5-hydroxytryptamine-2A (5-HT2A ) receptor agonist that is used recreationally worldwide. Interest in LSD research in humans waned after the 1970s, although the use of LSD in psychiatric research and ...
E. Liakoni, Kratschmar, Denise V., Dolder, P. C., M. E. Liechti, Kratschmar, D V, Dolder, P C, P. C. Dolder, Liechti, M E, Strajhar, P, Rentsch, K. M., Strajhar, Petra, Schmid, Y., Rentsch, K M, Liakoni, E., Y. Schmid, K. M. Rentsch, Schmid, Y, Liechti, Matthias E., A. Odermatt, Odermatt, A, Odermatt, Alex, P. Strajhar, D. V. Kratschmar, Liakoni, Evangelia   +23 more
core   +1 more source

sj-docx-1-jop-10.1177_02698811221099650 – Supplemental material for Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD)

, 2022
Supplemental material, sj-docx-1-jop-10.1177_02698811221099650 for Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD) by Emma I Kopra, Jason A Ferris, James J Rucker, Benjamin ...
Jason A Ferris (12385796), Benjamin McClure (12855027), Allan H Young (9559350), Emma I Kopra (12385793), Adam R Winstock (5196926), James J Rucker (9908841), Caroline S Copeland (12855030)   +6 more
core   +1 more source

Exploring new avenues: Psychedelic‐assisted therapy for young people

British Journal of Clinical Pharmacology, EarlyView.
Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou, Dasha Nicholls, David J. Nutt, Martina Di Simplicio   +3 more
wiley   +1 more source

Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases [PDF]

, 2014
A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-assisted psychotherapy in 12 patients with anxiety associated with life-threatening diseases.
Doblin, Rick, Yazar-Klosinski, Berra, Passie, Torsten, Brenneisen, Rudolf, Brenneisen, Rudolf Max, Gasser, Peter, Holstein, Dominique, Michel, Yvonne, Holstein, Dominique Hans   +8 more
core   +1 more source

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part II. Lysergic acid diethylamide (LSD)

, 2023
Background: Lysergic acid diethylamide (LSD) is a hallucinogenic agent. In the mid-20th century, it was used to augment psychoanalysis and to treat alcohol use disorder. However, LSD was banned in 1970 in part due to concerns that it could bring about or
Chelsey Fasano, Owen S. Muir, Bryce D. Beutler, Viviana D. Evans, Kenneth Shinozuka, Alejandro Arenas, Burton J. Tabaac, Kirsten Cherian   +7 more
core   +1 more source

Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis

Scientific Reports, 2021
Lysergic acid diethylamide (LSD) is a classic psychedelic substance that is used recreationally and investigated in psychiatric research. There are no pharmacogenetic studies on LSD.
Patrick Vizeli, Isabelle Straumann, Friederike Holze, Yasmin Schmid, Patrick C. Dolder, Matthias E. Liechti   +5 more
doaj   +1 more source

The Serotonin 2B (5‐HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression

Clinical Pharmacology &Therapeutics, EarlyView.
Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks.
Gia Han Le, Sabrina Wong, Danica E. Johnson, Diana K. Orsini, Yang Jing Zheng, Kayla M. Teopiz, Christine E. Dri, Joshua D. Rosenblat, Roger S. McIntyre   +8 more
wiley   +1 more source

Effect of lysergic acid diethylamide and its brom analogue on arterial hypertension in the rat

, 1961
Subcutaneous administration of d-lysergic acid diethylamide (LSD) or 2-brom- d-lysergic acid diethylamide (BOL) markedly lowered the blood pressure of renal hypertensive rats.
George H. Fried, William Antopol, Stephen Sugaar, John Kalberer   +3 more
core   +1 more source

Recreational Drug Use at a Music Festival: A Dual Approach Using Hair Biomarkers Analysis and Participant Self‐Reported Drug Use

Drug Testing and Analysis, EarlyView.
Combined self‐report and hair analysis in festival attendees (n = 249) revealed substantial discrepancies in drug use reporting, particularly for stimulants and dissociatives. This integrated approach enhances detection of poly‐drug use and provides a more reliable basis for monitoring and harm‐reduction strategies.
A. Y. Simão, T. Rosado, M. Barroso, M. Andraus, E. Gallardo   +4 more
wiley   +1 more source

Does LSD Have Any Therapeutical Value In Mental Disorders? A Non-Systemic Review

European Psychiatry, 2022
Introduction Lysergic acid diethylamide (LSD) a semi synthetic hallucinogen, was first synthetized by Albert Hofmann in 1938 and its psychological properties were not discovered until 1943.
L. Silva, L. Bravo
doaj   +1 more source